{
  "docId": "019de076-906b-74a9-92f8-5c2872231d60",
  "docSlug": "a8776e7183e96a109d1a49143fc2ff88",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 26,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-906b-74a9-92f8-5c2872231d60/12",
  "deckHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60",
  "deckJsonHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60.json",
  "deckAnchorHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Frequency of exhausted vs effector T-cells at baseline, EOT, and follow-up.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f308958-4d6d-456d-aa61-20eb5b7e2ff5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.75,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Longitudinal patient data (Patients 42, 43, 48) showing HBsAg, ALT, and T-cell proliferation over time.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f1b7cae-eaa2-49d1-bdb7-b81b2e0bc058",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.22,
        "x": 0.75,
        "y": 0.5
      },
      "kind": "list",
      "text": "Upregulation of HBV-specific T-cell activation markers observed in all 7 patients assessed to date. Two profiles of HBV-specific T cell IFN-y responses observed. Elevation between Wk 16-28 which coincides with nadir of HBsAg reduction. Elevation after imdusiran dosing completed, between Wk 48-60.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1372ecc-23b9-4142-98ed-03cb4b8a9c75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.1,
        "x": 0.55,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Data presented at EASL 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aca44f4-c527-45f9-b819-b082aef54ddb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "AB-729-001: Treatment with Imdusiran Reactivates HBV Specific Immunity in Some Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f43867a2-2aee-4230-a038-36444b8385ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 8,
      "beatId": "b0891741-a256-4e4e-a8d2-65a9f9895b7f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline and clinical trial results as a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 11,
      "beatId": "bb704643-20a7-459a-9df1-5b5cea9225d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical trial results and data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9268b1b4-494b-44ee-8454-6a997fc0aa8b",
      "evidence": "The document presents clinical trial results and data.",
      "position": 1,
      "objective": "Can Imdusiran RNAi therapeutic and AB-101 oral PD-L1 inhibitor provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}